|
|
Prepublished online as a Blood First Edition Paper on June 12, 2003; DOI 10.1182/blood-2003-03-0807.
 Previous Article | Table of Contents | Next Article 
Blood, 1 October 2003, Vol. 102, No. 7, pp. 2670-2677
RED CELLS
Labile plasma iron in iron overload: redox activity and susceptibility to chelation
Breno P. Esposito,
William Breuer,
Pornpan Sirankapracha,
Pensri Pootrakul,
Chaim Hershko, and
Z. Ioav Cabantchik
From the Department of Biological Chemistry, Institute of Life Sciences, Hebrew University of Jerusalem, Israel; Thalassemia Research Center, Institute of Science and Technology for Research and Development, Mahidol University, Salaya Campus, Nakornpathom, Thailand; and the Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Plasma non-transferrin-bound-iron (NTBI) is believed to be responsible for catalyzing the formation of reactive radicals in the circulation of iron overloaded subjects, resulting in accumulation of oxidation products. We assessed the redox active component of NTBI in the plasma of healthy and  -thalassemic patients. The labile plasma iron (LPI) was determined with the fluorogenic dihydrorhodamine 123 by monitoring the generation of reactive radicals prompted by ascorbate but blocked by iron chelators. The assay was LPI specific since it was generated by physiologic concentrations of ascorbate, involved no sample manipulation, and was blocked by iron chelators that bind iron selectively. LPI, essentially absent from sera of healthy individuals, was present in those of -thalassemia patients at levels (1-16 µM) that correlated significantly with those of NTBI measured as mobilizer-dependent chelatable iron or desferrioxamine chelatable iron. Oral treatment of patients with deferiprone (L1) raised plasma NTBI due to iron mobilization but did not lead to LPI appearance, indicating that L1-chelated iron in plasma was not redox active. Moreover, oral L1 treatment eliminated LPI in patients. The approach enabled the assessment of LPI susceptibility to in vivo or in vitro chelation and the potential of LPI to cause tissue damage, as found in iron overload conditions. (Blood. 2003;102:2670-2677)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. B Zimmermann, S. Fucharoen, P. Winichagoon, P. Sirankapracha, C. Zeder, S. Gowachirapant, K. Judprasong, T. Tanno, J. L Miller, and R. F Hurrell
Iron metabolism in heterozygotes for hemoglobin E (HbE), {alpha}-thalassemia 1, or {beta}-thalassemia and in compound heterozygotes for HbE/{beta}-thalassemia
Am. J. Clinical Nutrition,
October 1, 2008;
88(4):
1026 - 1031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. R. Lane and A. Lawen
Non-transferrin Iron Reduction and Uptake Are Regulated by Transmembrane Ascorbate Cycling in K562 Cells
J. Biol. Chem.,
May 9, 2008;
283(19):
12701 - 12708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-S. Sohn, W. Breuer, A. Munnich, and Z. I. Cabantchik
Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications
Blood,
February 1, 2008;
111(3):
1690 - 1699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cazzola, M. G. Della Porta, and L. Malcovati
Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes
Hematology,
January 1, 2008;
2008(1):
166 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ternes, B. Scheiber-Mojdehkar, G. Landgraf, H. Goldenberg, and B. Sturm
Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages
Nephrol. Dial. Transplant.,
October 1, 2007;
22(10):
2824 - 2830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gardenghi, M. F. Marongiu, P. Ramos, E. Guy, L. Breda, A. Chadburn, Y. Liu, N. Amariglio, G. Rechavi, E. A. Rachmilewitz, et al.
Ineffective erythropoiesis in -thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin
Blood,
June 1, 2007;
109(11):
5027 - 5035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Blum, R. Asaf, J. Guetta, R. Miller-Lotan, R. Asleh, R. Kremer, N. S. Levy, F. G. Berger, D. Aronson, X. Fu, et al.
Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice
J. Am. Coll. Cardiol.,
January 2, 2007;
49(1):
82 - 87.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Glickstein, R. B. El, G. Link, W. Breuer, A. M. Konijn, C. Hershko, H. Nick, and Z. I. Cabantchik
Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences
Blood,
November 1, 2006;
108(9):
3195 - 3203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A M Emara, R S El Kelany, and K A Moustafa
Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats
Human and Experimental Toxicology,
July 1, 2006;
25(7):
375 - 385.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Glickstein, R. Ben El, M. Shvartsman, and Z. I. Cabantchik
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells
Blood,
November 1, 2005;
106(9):
3242 - 3250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Rund and E. Rachmilewitz
{beta}-Thalassemia
N. Engl. J. Med.,
September 15, 2005;
353(11):
1135 - 1146.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Le Lan, O. Loreal, T. Cohen, M. Ropert, H. Glickstein, F. Laine, M. Pouchard, Y. Deugnier, A. Le Treut, W. Breuer, et al.
Redox active plasma iron in C282Y/C282Y hemochromatosis
Blood,
June 1, 2005;
105(11):
4527 - 4531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Asleh, J. Guetta, S. Kalet-Litman, R. Miller-Lotan, and A. P. Levy
Haptoglobin Genotype- and Diabetes-Dependent Differences in Iron-Mediated Oxidative Stress In Vitro and In Vivo
Circ. Res.,
March 4, 2005;
96(4):
435 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E.R. Kartikasari, N. A. Georgiou, F. L.J. Visseren, H. van Kats-Renaud, B. S. van Asbeck, and J. J.M. Marx
Intracellular Labile Iron Modulates Adhesion of Human Monocytes to Human Endothelial Cells
Arterioscler Thromb Vasc Biol,
December 1, 2004;
24(12):
2257 - 2262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sulieman, R. Asleh, Z. I. Cabantchik, W. Breuer, D. Aronson, A. Suleiman, R. Miller-Lotan, H. Hammerman, and A. P. Levy
Serum Chelatable Redox-Active Iron Is an Independent Predictor of Mortality After Myocardial Infarction in Individuals With Diabetes
Diabetes Care,
November 1, 2004;
27(11):
2730 - 2732.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-C. Tarng, S.-C. Hung, and T.-P. Huang
Effect of Intravenous Ascorbic Acid Medication on Serum Levels of Soluble Transferrin Receptor in Hemodialysis Patients
J. Am. Soc. Nephrol.,
September 1, 2004;
15(9):
2486 - 2493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Pootrakul, W. Breuer, M. Sametband, P. Sirankapracha, C. Hershko, and Z. I. Cabantchik
Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded {beta}-thalassemia/HbE patients treated with an oral chelator
Blood,
September 1, 2004;
104(5):
1504 - 1510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Scheiber-Mojdehkar, B. Lutzky, R. Schaufler, B. Sturm, and H. Goldenberg
Non-Transferrin-Bound Iron in the Serum of Hemodialysis Patients Who Receive Ferric Saccharate: No Correlation to Peroxide Generation
J. Am. Soc. Nephrol.,
June 1, 2004;
15(6):
1648 - 1655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Cohen, R. Galanello, D. J. Pennell, M. J. Cunningham, and E. Vichinsky
Thalassemia
Hematology,
January 1, 2004;
2004(1):
14 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
